Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

HOWL
Werewolf Therapeutics, Inc. Common Stock
stock NASDAQ

At Close
May 12, 2025 3:59:48 PM EDT
1.01USD+26.282%(+0.21)544,324
1.00Bid   1.02Ask   0.02Spread
Pre-market
May 12, 2025 9:19:30 AM EDT
0.8401USD+5.039%(+0.0403)625
After-hours
May 12, 2025 4:53:30 PM EDT
1.02USD+0.990%(+0.01)5,264
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 11, 2022
10:38AM EST  52 Weeks High And Low Article   Benzinga
Jan 5, 2022
08:00AM EST  Werewolf Therapeutics to Present at the H.C. Wainwright Bioconnect   GlobeNewswire Inc
Dec 14, 2021
04:02PM EST  Werewolf Therapeutics Reports Will Be Added To Nasdaq Biotech Index, Effective Monday, Dec. 20, 2021   Benzinga
04:01PM EST  Werewolf Therapeutics Added to the Nasdaq Biotechnology Index   GlobeNewswire Inc
Dec 1, 2021
08:15AM EST  Werewolf Therapeutics To Present Preclinical Data On INDUKINE Molecules At 63rd American Society Of Hematology Annual Meeting   Benzinga
08:00AM EST  Werewolf Therapeutics to Present Preclinical Data on   GlobeNewswire Inc
Nov 19, 2021
07:04AM EST  SVB Leerink Maintains Outperform on Werewolf Therapeutics, Lowers Price Target to $28   Benzinga
Nov 10, 2021
07:56AM EST  Werewolf Therapeutics Q3 Loss Per Share $0.51 Vs Loss $6.61 Last Year   RTTNews
07:54AM EST  Werewolf Therapeutics Q3 EPS $(0.51) Up From $(6.61) YoY   Benzinga
07:00AM EST  -Clinical Trial Collaboration with Merck for WTX-124 INDUKINE Program-   GlobeNewswire Inc
Nov 8, 2021
08:03AM EST  Werewolf Therapeutics, Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the bodys immune system for the treatment of cancer, today announced that management will present at the following investor conferences:   GlobeNewswire Inc
Oct 27, 2021
07:30AM EDT  Werewolf Therapeutics to Present Data on its   GlobeNewswire Inc
Sep 14, 2021
08:00AM EDT  Werewolf Therapeutics, Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the bodys immune system for the treatment of cancer, today announced that members of its leadership team will present at the Next-Gen Cytokine Therapeutics Summit on September 22.   GlobeNewswire Inc
Sep 10, 2021
07:36PM EDT  B of A Securities Initiates Coverage On Werewolf Therapeutics with Buy Rating, Announces Price Target of $26   Benzinga
Sep 8, 2021
08:00AM EDT  Werewolf Therapeutics, Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the bodys immune system for the treatment of cancer, today announced it will present at the H. C. Wainwright 23rd Annual Global Investment Conference on September 13-15.   GlobeNewswire Inc
Aug 18, 2021
08:02AM EDT  Biopharmaceutical company Werewolf Therapeutics, Inc. (HOWL) announced Wednesday that it has entered into a clinical trial collaboration and supply agreement with Merck & Co Inc. (MRK), known as MSD outside the U.S. and Canada, to evaluate WTX-124, in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 (programmed death receptor-1) therapy.   RTTNews
07:42AM EDT  Werewolf Therapeutics Collaborates With Merck On WTX-124 INDUKINE Program   RTTNews
07:31AM EDT  Werewolf Therapeutics Announces Clinical Trial Collaboration With Merck On Its WTX-124 INDUKINE Program   Benzinga
07:30AM EDT  Werewolf Therapeutics Announces Clinical Trial Collaboration with   GlobeNewswire Inc
Aug 12, 2021
07:12AM EDT  Werewolf Therapeutics Q2 EPS $(3.82) Down From $0.22 YoY   Benzinga
07:00AM EDT  Werewolf Therapeutics, Inc. (the Company or Werewolf) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the bodys immune system for the treatment of cancer, today provided a business update and reported financial results for the quarter ended June30, 2021.   GlobeNewswire Inc
Jun 24, 2021
07:00AM EDT  Werewolf Therapeutics, Inc., an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the bodys immune system for the treatment of cancer, today announced that it will be added to the Russell 2000 Index at the conclusion of the Russell US Indexes annual reconstitution on June 28, 2021.   GlobeNewswire Inc
Jun 15, 2021
07:12AM EDT  Werewolf Therapeutics Appoints Chulani Karunatilake As Chief Technology Officer   RTTNews
07:00AM EDT  Veteran life sciences executive brings more than 30 years CMC and product development strategy expertise to rapidly advance programs and oversee manufacturing   GlobeNewswire Inc
Jun 10, 2021
07:06AM EDT  Werewolf Therapeutics Reports Q1 Net Loss Of $7.4M, Compared To $3.8M YoY   Benzinga
07:00AM EDT  Werewolf Therapeutics, Inc. (the Company or Werewolf) (NASDAQ: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the bodys immune system for the treatment of cancer, today announced financial results for the quarter ended March31, 2021.   GlobeNewswire Inc
May 28, 2021
07:00AM EDT  Werewolf Therapeutics, Inc. (NASDAQ: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the bodys immune system for the treatment of cancer, today announced the appointment of Mike Sherman, chief executive officer of Chimerix, Inc., as a member of its board of directors.   GlobeNewswire Inc
May 27, 2021
07:30AM EDT  Werewolf Therapeutics to Present at Jefferies Virtual Healthcare   GlobeNewswire Inc
May 25, 2021
10:02AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For May 25, 2021   Benzinga
07:23AM EDT  Evercore ISI Group Initiates Coverage On Werewolf Therapeutics with Outperform Rating, Announces Price Target of $23   Benzinga
07:13AM EDT  SVB Leerink Initiates Coverage On Werewolf Therapeutics with Outperform Rating, Announces Price Target of $29   Benzinga
07:04AM EDT  Jefferies Initiates Coverage On Werewolf Therapeutics with Buy Rating, Announces Price Target of $22   Benzinga
07:00AM EDT  HC Wainwright & Co. Initiates Coverage On Werewolf Therapeutics with Buy Rating, Announces Price Target of $32   Benzinga
May 23, 2021
10:06AM EDT  The Week Ahead In Biotech (May 23-29): Eton, Lantheus FDA Decisions, Adcom Test For Provention, Chiasma Data Presentation   Benzinga
May 14, 2021
07:59AM EDT  The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts   Benzinga
May 12, 2021
08:57AM EDT  The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron   Benzinga
May 8, 2021
12:10PM EDT  The Past Week's Notable Insider Buys: Amphenol, Aldeyra, Werewolf Therapeutics And More   Benzinga
May 7, 2021
07:40AM EDT  The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs   Benzinga
May 4, 2021
08:10AM EDT  The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data   Benzinga
Apr 30, 2021
10:37AM EDT  Werewolf Therapeutics Shares Open For Trade At $18.21; IPO Priced At $16/Share   Benzinga
10:19AM EDT  Werewolf Therapeutics Indicating $25   Benzinga
09:30AM EDT  Werewolf Therapeutics Shares Will Open For Quote At 9:50 a.m. EST, Expected To Open For Trade After 10 a.m. EST; IPO Priced At $16/Share   Benzinga
05:33AM EDT  Werewolf Therapeutics Priced 7.5M Share IPO @$16/Share   Benzinga


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC